Global Longlife Hospital and Research Ltd Fair Value
GLHRL · Healthcare · Current price ₹12.39
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹17 | -7% ROE fading to 12% over ~3 yrs, on ₹23 book |
| Relative P/E | — | Needs positive EPS |
| Graham floor | — | Needs positive EPS |
| Analyst target | — | No analyst coverage |
Is Global Longlife Hospital and Research Ltd undervalued?
DocStoX estimates the fair value of Global Longlife Hospital and Research Ltd at ₹17 per share, versus the current market price of ₹12. That puts the stock about +37.2% below our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 1 independent method: Residual income (₹17). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹14 (bear) to ₹17 (base) to ₹20 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on Global Longlife Hospital and Research Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.